Louise R. Rodino-Klapac, Ph.D.
Affiliations: | 2005 | Ohio State University, Columbus, Columbus, OH |
Area:
Motor Axon GuidanceGoogle:
"Louise Rodino-Klapac"Mean distance: 17.91 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Christine Beattie | grad student | 2005 | Ohio State | |
| (Genetic analysis of motor axon pathfinding in zebrafish.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mendell JR, Pozsgai ER, Lewis S, et al. (2024) Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results. Nature Medicine |
| Potter RA, Griffin DA, Heller KN, et al. (2023) Expression and function of Four AAV-based constructs for dystrophin restoration in the mdx mouse model of duchenne muscular dystrophy. Biology Open |
| Seo YE, Baine SH, Kempton AN, et al. (2023) Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model. Molecular Therapy. Methods & Clinical Development. 28: 284-299 |
| Crowe KE, Zygmunt DA, Heller K, et al. (2021) Visualizing Muscle Sialic Acid Expression in the GNED207VTgGne-/- Cmah-/- Model of GNE Myopathy: A Comparison of Dietary and Gene Therapy Approaches. Journal of Neuromuscular Diseases |
| Potter RA, Griffin DA, Heller KN, et al. (2021) Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the Mouse Model of Duchenne Muscular Dystrophy. Human Gene Therapy |
| Griffin DA, Pozsgai ER, Heller KN, et al. (2020) Pre-clinical Systemic Delivery of Adeno-Associated Alpha-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy. Human Gene Therapy |
| Mendell JR, Sahenk Z, Lehman K, et al. (2020) Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. Jama Neurology |
| Asher DR, Thapa K, Dharia SD, et al. (2020) Clinical Development on the Frontier: Gene Therapy for Duchenne Muscular Dystrophy. Expert Opinion On Biological Therapy |
| Alfano LN, Charleston JS, Connolly AM, et al. (2019) Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine. 98: e15858 |
| Mendell JR, Chicoine LG, Al-Zaidy SA, et al. (2019) Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D (LGMD2D). Human Gene Therapy |